Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. dominated the market today, gaining €0.28 (4.420%).
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 8 € shows a slightly positive potential of 16.86% compared to the current price of 6.85 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 4.420% | -6.193% | -12.634% | 20.954% | 8.409% | 202.920% | 249.108% |
| Evolus Inc | 2.620% | 5.140% | -10.131% | 4.419% | 0.587% | -38.404% | -43.485% |
| Heron Therapeutics Inc. | -2.600% | -2.739% | 12.453% | -73.548% | -62.388% | -72.792% | -95.833% |
| Rhythm Pharmaceuticals | -1.050% | 3.279% | -1.563% | 24.342% | 1.070% | 333.486% | 707.692% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat